These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33251343)

  • 1. Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer.
    Wilson GD; Wilson TG; Hanna A; Dabjan M; Buelow K; Torma J; Marples B; Galoforo S
    Clin Transl Radiat Oncol; 2021 Jan; 26():15-23. PubMed ID: 33251343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
    Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
    PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma.
    Williams JP; Kim I; Ito E; Shi W; Yue S; Siu LL; Waldron J; O'Sullivan B; Yip KW; Liu FF
    PLoS One; 2014; 9(5):e98557. PubMed ID: 24853121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual blockade of PI3K and MEK in combination with radiation in head and neck cancer.
    Blas K; Wilson TG; Tonlaar N; Galoforo S; Hana A; Marples B; Wilson GD
    Clin Transl Radiat Oncol; 2018 Jun; 11():1-10. PubMed ID: 30014041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.
    Leiker AJ; DeGraff W; Choudhuri R; Sowers AL; Thetford A; Cook JA; Van Waes C; Mitchell JB
    Clin Cancer Res; 2015 Jun; 21(12):2792-801. PubMed ID: 25724523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts.
    Brana I; Pham NA; Kim L; Sakashita S; Li M; Ng C; Wang Y; Loparco P; Sierra R; Wang L; Clarke BA; Neel BG; Siu LL; Tsao MS
    Oncotarget; 2017 Oct; 8(49):84659-84670. PubMed ID: 29156674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer.
    Tonlaar N; Galoforo S; Thibodeau BJ; Ahmed S; Wilson TG; Yumpo Cardenas P; Marples B; Wilson GD
    Radiother Oncol; 2017 Sep; 124(3):504-512. PubMed ID: 28823407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384.
    Zhu Y; Shah K
    Cancer Biol Ther; 2014 Jun; 15(6):815-22. PubMed ID: 24658109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
    Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
    Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
    Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models.
    Rossetti S; Broege A; Sen A; Khan S; MacNeil I; Molden J; Kopher R; Schulz S; Laing L
    NPJ Breast Cancer; 2024 Jun; 10(1):40. PubMed ID: 38839777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
    Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
    Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
    Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
    Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of the dual PI3K/mTOR inhibitor gedatolisib and the involvement of ABCB1 in gedatolisib resistance in canine tumor cells.
    Murase Y; Hosoya K; Sato T; Kim S; Okumura M
    Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35088890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer.
    Keam B; Kim S; Ahn YO; Kim TM; Lee SH; Kim DW; Heo DS
    Anticancer Res; 2015 Jan; 35(1):175-82. PubMed ID: 25550549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX.
    Iezzi A; Caiola E; Broggini M
    Transl Oncol; 2016 Oct; 9(5):458-465. PubMed ID: 27751351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
    Kalous O; Conklin D; Desai AJ; O'Brien NA; Ginther C; Anderson L; Cohen DJ; Britten CD; Taylor I; Christensen JG; Slamon DJ; Finn RS
    Mol Cancer Ther; 2012 Sep; 11(9):1978-87. PubMed ID: 22761403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.
    Bozec A; Ebran N; Radosevic-Robin N; Sudaka A; Monteverde M; Toussan N; Etienne-Grimaldi MC; Nigro CL; Merlano M; Penault-Llorca F; Milano G
    Laryngoscope; 2016 Apr; 126(4):E156-63. PubMed ID: 26597440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors.
    Endersby R; Whitehouse J; Hii H; Greenall SA; Johns TG; Gottardo NG
    Neoplasia; 2018 May; 20(5):432-442. PubMed ID: 29574250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
    Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
    Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.